Practical Insights on How to Improve Comprehensive Biomarker Testing in Advanced Non-Small Cell Lung Cancer

Sign-up for the second in a 6-part series, titled, “Proactive Interventions for the Prior Authorization Process”

Explore opportunities to expand multidisciplinary care collaboration and coordination to improve care for patients with non-melanoma skin cancers.

Raise awareness among cancer programs of new treatment options for newly diagnosed patients with multiple myeloma ineligible for transplant.

Sign-up for the first in a 6-part series, titled, “Proactive Interventions for the Prior Authorization Process”

Oncology state society leaders from the Appalachian Community Cancer Alliance share an introduction to the Alliance, their insights into the unique needs of the Appalachian region and beyond, how the Alliance is responding and how you can get involved.

This educational initiative will focus on multidisciplinary education surrounding TILs, with an emphasis on the importance of implementing clinical trials in the community setting.

Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors. Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities.

Testing for measurable residual disease can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia. Unfortunately, routine MRD testing is variable. This three-part webinar series is aimed at building capacity to implement, expand, and sustain MRD testing for patients with adult B-cell ALL at cancer programs and practices of all resource levels.

The COVID-19 pandemic has affected treatment patterns for patients with CLL. Javier Munoz, MD, MS, FACP, Senior Associate Consultant in the Division of Hematology and Medical Oncology at the Mayo Clinic (Arizona) will discuss considerations for treating patients with CLL in the pandemic--including options for treatment, best timing for treatment, and any changes to the usual treatment regimen. Dr. Munoz will also explore what care may look like for patients with CLL beyond COVID-19.